Literature DB >> 33334367

Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer.

Sheng Wu1,2, Katja Nitschke1, Thomas Stefan Worst1, Alexander Fierek1, Cleo-Aron Weis3, Markus Eckstein4, Stefan Porubsky3, Maximilian Kriegmair1, Philipp Erben5.   

Abstract

BACKGROUND: Growing evidence supports the pivotal role of long non-coding RNAs (lncRNAs) in the regulation of cancer development and progression. Their expression patterns and biological function in muscle invasive bladder cancer (MIBC) remain elusive.
METHODS: Transcript levels of lncRNA miR-31 host gene (MIR31HG) and its splice variants were measured in our MIBC cohort (n = 102) by qRT-PCR, and validated in silico by the TCGA cohort (n = 370). Kaplan-Meier and multiple Cox regression analysis were conducted to evaluate the survival significance of MIR31HG and its splice variants. Functional experiments were performed to examine the proliferation and migration abilities of MIR31HG and its splice variants by knockdown approaches.
RESULTS: In this study, a decreased expression of MIR31HG was found in bladder cancer cells and tissues, except in the basal subtype. Survival analysis showed that high expression of MIR31HG was associated with poor overall survival (OS) and disease-free survival (DFS) in patients with MIBC of basal subtype. Two splice variants of MIR31HG lacking exon 1 (MIR31HGΔE1) and exon 3 (MIR31HGΔE3) were identified to have specific expression patterns in different molecular subtypes of our MIBC cohort. MIR31HGΔE3 was highly expressed in basal subtype tumors. A high expression of MIR31HGΔE1 and MIR31HGΔE3 was associated with worse OS and DFS in our cohort. In vitro experiments revealed that knockdown of MIR31HG inhibits cell proliferation, colony formation, and migration in bladder cancer. Cell proliferation and migration assays after knockdown of splice variants of MIR31HG showed corresponding roles for the full-length transcript.
CONCLUSIONS: Our study demonstrates that MIR31HG and its splice variants could serve as biomarkers for the classification and prognosis prediction of patients with MIBC.

Entities:  

Keywords:  Biomarker; LncRNA; MIR31HG; Molecular subtype; Muscle invasive bladder cancer

Year:  2020        PMID: 33334367     DOI: 10.1186/s13046-020-01795-5

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  48 in total

1.  Three differentiation states risk-stratify bladder cancer into distinct subtypes.

Authors:  Jens-Peter Volkmer; Debashis Sahoo; Robert K Chin; Philip Levy Ho; Chad Tang; Antonina V Kurtova; Stephen B Willingham; Senthil K Pazhanisamy; Humberto Contreras-Trujillo; Theresa A Storm; Yair Lotan; Andrew H Beck; Benjamin I Chung; Ash A Alizadeh; Guilherme Godoy; Seth P Lerner; Matt van de Rijn; Linda D Shortliffe; Irving L Weissman; Keith S Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-19       Impact factor: 11.205

Review 2.  Molecular mechanisms of long noncoding RNAs.

Authors:  Kevin C Wang; Howard Y Chang
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

Review 3.  Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions.

Authors:  Jeanny B Aragon-Ching; Ryan P Werntz; Anthony L Zietman; Gary D Steinberg
Journal:  Am Soc Clin Oncol Educ Book       Date:  2018-05-23

4.  Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells.

Authors:  Yongguo Shi; Jianwei Lu; Jing Zhou; Xueming Tan; Ye He; Jie Ding; Yun Tian; Li Wang; Keming Wang
Journal:  Biochem Biophys Res Commun       Date:  2014-03-12       Impact factor: 3.575

5.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.

Authors:  Marko Babjuk; Andreas Böhle; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Virginia Hernández; Eero Kaasinen; Joan Palou; Morgan Rouprêt; Bas W G van Rhijn; Shahrokh F Shariat; Viktor Soukup; Richard J Sylvester; Richard Zigeuner
Journal:  Eur Urol       Date:  2016-06-17       Impact factor: 20.096

6.  [Effect of preanesthetic medication in general anesthesia on hemodynamics in surgically treated patients with ischemic heart disease].

Authors:  R Golański; A Iwaszkiewicz; J Rychter; W Kuroczyński
Journal:  Pol Tyg Lek       Date:  1985-04-22

7.  Clinical and molecular characteristics of bladder urothelial carcinoma subtypes.

Authors:  Ying Li; Kai Yang; Ke Li; He Liu; Siqi Zhao; Mingli Jiao; Xinru Fu
Journal:  J Cell Biochem       Date:  2018-12-12       Impact factor: 4.429

Review 8.  The emergence of lncRNAs in cancer biology.

Authors:  John R Prensner; Arul M Chinnaiyan
Journal:  Cancer Discov       Date:  2011-10       Impact factor: 39.397

Review 9.  The functional role of long non-coding RNA in human carcinomas.

Authors:  Ewan A Gibb; Carolyn J Brown; Wan L Lam
Journal:  Mol Cancer       Date:  2011-04-13       Impact factor: 27.401

Review 10.  Long Non-coding RNAs in Urologic Malignancies: Functional Roles and Clinical Translation.

Authors:  Jiajia Chen; Zhijun Miao; Boxin Xue; Yuxi Shan; Guobin Weng; Bairong Shen
Journal:  J Cancer       Date:  2016-08-15       Impact factor: 4.207

View more
  3 in total

1.  MIR31HG Expression Predicts Poor Prognosis and Promotes Colorectal Cancer Progression.

Authors:  Jianlong Wang; Bin Liu; Jiewei Cao; Lianmei Zhao; Guiying Wang
Journal:  Cancer Manag Res       Date:  2022-06-16       Impact factor: 3.602

2.  RNA Microarray-Based Comparison of Innate Immune Phenotypes between Human THP-1 Macrophages Stimulated with Two BCG Strains.

Authors:  Gabriela Molina-Olvera; Claudia I Rivas-Ortiz; Alejandro Schcolnik-Cabrera; Antonia I Castillo-Rodal; Yolanda López-Vidal
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

3.  Long Noncoding RNA GAS5 Inhibits Osteogenic Differentiation through MicroRNA 382-3p/TAF1 Signaling.

Authors:  Yuxin Song; Hui Zhang; Zhengdong Song; Yang Yang; Suifeng Zhang; Wenji Wang; Shanyong Zhang
Journal:  Mol Cell Biol       Date:  2021-12-13       Impact factor: 5.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.